How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

43,022 results for

antibiotic resistance

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

31761. Diabetes and Periodontal Therapy Trial

) at 6 months post-randomization in subjects with type 2 diabetes and untreated, moderate to advanced chronic periodontitis. The secondary aims of the study are to: evaluate whether 6 month (or shorter-term (3 month)) changes in clinical measures of chronic periodontitis (gingival index, bleeding on probing, probing depth, clinical attachment level) are related to changes in HbA1c and fasting glucose or insulin resistance as measured by the Homeostasis Model Assessment 2 (HOMA2). assess the 3 month (...) within the last 30 days because of hyperglycemia or diabetes complications. Chronic or continuous use (daily for more than 7 consecutive days) of nonsteroidal anti-inflammatory drugs within the preceding 2 months, other than low dose aspirin (e.g. 75-325 mg/day). Receiving chronic treatment with systemic corticosteroids, cyclosporine or other systemic immunosuppressive drugs Chronic treatment with systemic antibiotics (antibiotics for > 7 consecutive days within 30 days of baseline visit). Currently

2009 Clinical Trials

31762. Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment

Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment Clearance of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clearance (...) of Nasal Staphylococcus Aureus With Triple Antibiotic Ointment The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00997139 Recruitment Status : Completed First Posted : October 19, 2009 Results First Posted : May 8, 2012 Last Update Posted : January 5, 2015 Sponsor: Northwestern University Information

2009 Clinical Trials

31763. Study of Adding Cetuximab to Chemotherapy for the Treatment of Advanced and/or Recurrent Cervical Cancer

, especially in recurrent or resistant disease. This study evaluates the activity of the addition of cetuximab to full doses of carboplatin and paclitaxel. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 108 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: Randomized Phase II Study of Carboplatin and Paclitaxel +/- Cetuximab, in Advanced (...) antibiotics. Symptomatic peripheral neuropathy >grade 2 according to the CTCAE. Congestive heart failure or angina pectoris even if it is medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled high risk hypertension or arrhythmia. Known hypersensitivity to the study drugs or to drugs with similar chemical structures. Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational drug within 30 days

2009 Clinical Trials

31764. Pilot Study to Compare the Pharmacokinetics Parameters in Plasma and Intracellular of Raltegravir Administered Once a Day in Adult Patients Infected With HIV

or disease Intervention/treatment Phase HIV Infections Drug: Raltegravir Phase 4 Detailed Description: HIV integrase is the enzyme responsible for transferring the DNA encoded by HIV to host chromosomes, a necessary step for the replication of retroviruses. Raltegravir (RAL) is the first integrase inhibitor approved for HIV treatment of patients infected by this virus. RAL has demonstrated a marked antiretroviral activity against HIV strains resistant to other antiretroviral drug families and high (...) was continuing inhibited even when RAL was washed from the culture medium from the 8 hours after infection, suggesting the possibility of a post-antibiotic effect of the drug. Either way, as in the case of transcriptase inhibitor nucleoside analogues, this lack of correlation between pharmacokinetics and pharmacodynamics of RAL may only be the result of intracellular accumulation of drug in blood lymphocytes peripheral, which in turn could be explained either by setting the RAL to the pre-integration complex

2009 Clinical Trials

31765. Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

. In addition, p53 overexpression correlates with tumor transformation and aggression and is associated with lower overall survival rates and resistance to chemotherapeutic intervention in cancer patients. Therefore, p53 appears to be a marker for a considerable number of human malignancies and represents a good target for immunotherapeutics. However, p53 cannot be used as a target for antibodies because it is not displayed independently on the cell surface. Instead, the p53 protein is processed (...) disease No known HIV positive No psychiatric illness/social situations that would limit study compliance No history or evidence of CNS disease No active systemic infection requiring parental antibiotic therapy No systemic steroid therapy required No prior organ allograft or allogeneic transplantation Not receiving chronic medication for asthma Not pregnant or nursing Fertile patients must use effective contraception Contacts and Locations Go to Information from the National Library of Medicine

2009 Clinical Trials

31766. Comparison of Intravenous Cefazolin Plus Oral Probenecid With Oral Cephalexin for the Treatment of Cellulitis

Inclusion Criteria: Patients presenting to the emergency department with a presumed diagnosis of mild to moderate skin and soft tissue infection Deemed well enough to be treated as an outpatient 19 years of age or older Exclusion Criteria: known allergy to study drugs known chronic kidney disease with a creatinine clearance <30 mL/min known previous methicillin-resistant staphylococcus aureus (MRSA) infection use of antibiotics for greater than 24 hours in the past 7 days wound/abscess requiring (...) antibiotics, those with mild-moderate infections are often treated with parenteral antibiotics. Current practice patterns in Canadian EDs indicate this patient population is often treated with intravenous cefazolin once daily along with oral probenecid and return to the ED or other ambulatory setting for daily medication administration and assessment. This parenteral regimen has been found to result in success rates comparable to studies which have evaluated treatment success with oral antibiotics

2009 Clinical Trials

31767. A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain

tissue culture cells). Number of Participants With Development of Oseltamivir-Resistant Influenza Virus [ Time Frame: 40 days ] The last positive viral isolate from each patient was tested for reduced sensitivity to oseltamivir. Phenotypic assay was performed to determine the susceptibility of the last positive viral isolate from each patient. If required, a genotypic assay to determine the contribution of both the neuraminidase (NA) and hemagglutinin (HA) genes to decreased susceptibility was also (...) [ Time Frame: Day 1 through Day 40 ] The number of participants who developed secondary illnesses due to influenza, including four pre-defined adverse events: otitis media, bronchitis, pneumonia, or sinusitis at any time during the study. Number of Participants Who Developed Secondary Illnesses That Were Treated With Antibiotics [ Time Frame: Day 1 through Day 40 ] The number of participants who developed secondary illnesses due to influenza, including otitis media, bronchitis, pneumonia

2009 Clinical Trials

31768. Biological Effects of Weight Loss In Older, Obese Women

understudied. ions). In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week throughout the entire study. During each exercise session, participants engaged in both aerobic activities (i.e., walking) and lower body resistance training of moderate intensity. The participants in the educational control group attended monthly health education lectures on topics relevant to older adults. It was hypothesized that participants assigned (...) oxidase inhibitors; systemic corticosteroids; antibiotics for HIV or TB; chemotherapeutic drugs; or current use of prescription weight-loss drugs). Physical limitations likely to prevent exercise participation (use of walker; breathing problems that limit physical activity). Conditions or behaviors likely to affect the conduct of the trial (e.g., unwilling or unable to give informed consent; unwilling to accept random assignment; likely to move out of area within next 2 years; unable to attend weekly

2009 Clinical Trials

31769. The Efficacy of Susceptibility Test -Driven Sequential Therapy as the Third Line Therapy for Refractory Helicobacter Pylori Infection

of these diseases. However, it was estimated that 15-20% of patients would fail from first line standard eradication therapy and need second line rescue therapy. About 15-30% of patient would fail from second line therapy and need to be rescued with third line therapy. The commonly used salvage regimens include (1) Bismuth based quadruple therapy (combined with ranitidine or PPI plus two antibiotics) (2) Levofloxacin or moxifloxacin or rifabutin based triple therapy. However, Bismuth is not available in many (...) been demonstrated that the eradication rate among patients with clarithromycin-resistant strains could be as high as 89%. According to the Maastricht III consensus meeting, it was recommended that susceptibility test should be done for patients who failed two treatments. Therefore, we aimed to assess the efficacy of susceptibility test driven sequential therapy as the third line therapy for those who fail from two standard eradication therapies. Methods: This will be a multi-center, open labeled

2009 Clinical Trials

31770. Pharmacokinetic and Pharmacodynamic Evaluation of Doripenem in Critically Ill Trauma Patients

dosing regimens. It is even more imperative at the present time to maximize PK/PD parameters since there are no new novel antimicrobial agents to treat resistant gram-negative infections. This approach allows us to achieve superior PD parameters and treat bacteria that would have been resistant to standard dosing due to higher minimum inhibitory concentrations (MICs). Doripenem exhibits time-dependent bactericidal activity and the pharmacodynamic parameter predicting clinical and bacteriologic (...) . There is little information on how drugs are cleared in critically ill patients and the wrong dose of a drug could make it ineffective. The investigators will use this information to predict the most reasonable dose to treat infections effectively in these patients. Condition or disease Intervention/treatment Phase Sepsis Drug: Doripenem Phase 4 Detailed Description: Understanding the pharmacokinetic (PK)/pharmacodynamic (PD) characteristics of an antibiotic can provide insight into developing appropriate

2009 Clinical Trials

31771. Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin

Ovarian Epithelial Cancer Drug: belinostat Drug: carboplatin Phase 2 Detailed Description: PRIMARY OBJECTIVES: I. To estimate the antitumor activity of belinostat and carboplatin in patients with persistent or recurrent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, measured by objective response rate and the frequency of progression- free survival at 6 months. II. To determine the nature and degree of toxicity of belinostat in combination with carboplatin in this cohort (...) months for 2 years and then every 6 months for 3 years. Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 29 participants Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Phase II Evaluation of Belinostat (NSC #726630) and Carboplatin (NSC #241240) in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

2009 Clinical Trials

31772. Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

-PV Biological: Bivalent rLukS-PV / rAT Biological: Placebo with adjuvant Biological: Placebo Phase 1 Phase 2 Detailed Description: Staphylococcus aureus is a leading cause of skin and soft tissue infections. Antibiotic resistance, such as seen with new community-acquired methicillin-resistant strains, presents a major challenge in treating and preventing these infections. Therefore, a preventative vaccine is considered a potentially better approach. This study assesses the safety (...) University of the Health Sciences: Staphylococcus aureus Skin and soft tissue infection Methicillin-resistant Staphylococcus aureus Recombinant alpha-toxoid (rAT) Recombinant LukS subunit of Panton-Valentine Leukocidin (rLukS-PV)

2009 Clinical Trials

31773. Phase 3b Study to Evaluate Advagraf in Combination With Mycophenolate Mofetil and Basiliximab in Liver Transplantation

using the Cockcroft and Gault formula [ Time Frame: 24 weeks ] Incidence of and time to first incidence of acute rejection [ Time Frame: 24 weeks ] Incidence of and time to first incidence of corticosteroid-resistant acute rejection [ Time Frame: 24 weeks ] Overall frequency of acute rejection episodes [ Time Frame: 24 weeks ] Incidence of and time to first incidence of biopsy confirmed acute rejection [ Time Frame: 24 weeks ] Incidence of and time to first incidence of biopsy confirmed (...) corticosteroid-resistant acute rejection [ Time Frame: 24 weeks ] Overall frequency of biopsy confirmed acute rejection episodes [ Time Frame: 24 weeks ] Severity of biopsy confirmed acute rejection episodes [ Time Frame: 24 weeks ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your

2009 Clinical Trials

31774. Study of the Pharmacokinetics of Daptomycin in Children With Renal Disease

events are one of the most common complications in children with chronic kidney disease. The incidence is highest in children with an access for dialysis, especially in those with catheters. Staphylococcal species account for more than 50% of access infections (ranging from 58-77%). Failure to clear the infection results in loss of dialysis access. Daptomycin is a new antibiotic that provides coverage against most gram positive bacteria including methicillin-resistant staphylococci, vancomycin (...) -intermediate Staphylococcus aureus, and vancomycin-resistant enterococci. The pharmacokinetics of daptomycin in children on dialysis, a group of patients who may need the medication the most, remains unknown. Children on HD or PD with suspected or confirmed infections due to gram-positive bacteria and who are concurrently treated with standard of care antibiotics will be considered for this study. Each patient will be given a onetime dose of Cubicin (daptomycin). After receiving daptomycin, serial blood

2009 Clinical Trials

31775. Muscle Derived Cell Therapy for Bladder Exstrophy Epispadias Induced Incontinence

Urology Grade III hydronephrosis (widely split renal pelvis, renal calices uniformly dilated, no parenchymal thinning) or Grade IV hydronephrosis (Grade III dilation plus parenchymal thinning). See Appendix D. Previous injection of bulking agents at the level of the bladder neck (bovine collagen or DEFLUX™) Positive urine culture resistant to preoperative oral antibiotic therapy Need for chronic or pulse steroids or history of other congenital or acquired condition that results in immunocompromise (...) resistance and rhabdosphincter contractility, MDC injection may permit more efficient bladder cycling and bladder expansion in Group 1 patients allowing them to proceed on to bladder neck reconstruction. This same increase in resistance and sphincter contractility may allow Group 2 patients to attain urinary continence and avoid any further reconstructive surgical procedures. Eligible and consented patients would undergo rectus muscle biopsy and immediately transferred to the Cell Therapy Lab for tissue

2009 Clinical Trials

31776. A Two Part Study of Peroral Insulin in Type 2 Diabetes

Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Male and female subjects with Type 2 diabetes who were diagnosed for a minimum of 6 months, age 30-65 years. Subjects on a stable dose of metformin for at least two months with a total daily dose of ≤ 2600 mg/day. Subjects demonstrating an insulin resistance value (IR) lower than 3 based on the HOMA-2 model (University of Oxford, 2004) at Screening 2. Hemoglobin A1c <9%. Fasting capillary blood glucose within the range 6.0-9.0 mmol/L (108-162 (...) Participation in a clinical trial within the prior 3 months History of GI surgery or known GI motility disorders. History of a serious infection, including but not limited to hepatitis, pneumonia, or pyelonephritis, or have been hospitalized or received intravenous antibiotics for an infection, during the previous two months. A chronic or recurrent infectious disease, including but not limited to, chronic renal infection, chronic chest infection (bronchiectasis), sinusitis, recurrent urinary tract infection

2009 Clinical Trials

31777. Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections

Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Topical Antibiotics for Prevention of Intensive Care Unit (ICU) Central Line Infections (ToPICL) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT00990392 Recruitment Status : Withdrawn (Change of practice to antibiotic impregnated catheters and large study published showing

2009 Clinical Trials

31778. Safety and Pharmacokinetics of Ascending Single Oral Doses of EDP-322 in Nonfasting and Fasting Healthy Volunteers

Intervention/treatment Phase Skin and Soft Tissue Infections Methicillin-resistant Staphylococcus Aureus Drug: EDP-322 Phase 1 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 67 participants Allocation: Randomized Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose: Treatment Official Title: A Randomized, Double-blind, Placebo-Controlled, Ascending Single-Dose Safety, Tolerability, and Pharmacokinetics Study (...) , PhD PPD Phase I Unit More Information Go to Layout table for additonal information Responsible Party: Maria T. Madison, Dir. Clinical Operations, Enanta Pharmaceuticals ClinicalTrials.gov Identifier: Other Study ID Numbers: EDP-322-007-001 First Posted: October 6, 2009 Last Update Posted: October 6, 2009 Last Verified: October 2009 Keywords provided by Enanta Pharmaceuticals: Macrolides Antibiotics Safety Tolerability Pharmacokinetics Phase I MRSA/SSTI Additional relevant MeSH terms: Layout table

2009 Clinical Trials

31779. Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.

≥0.8 g/24 hrs steroid-resistant, humoral, moderate/severe (BANFF grade ≥II) biopsy proven acute rejections multiple (2 or more) biopsy proven or treated acute rejections or acute rejections leading to relevant loss of renal function acute rejection or impairment of renal function (increase of serum creatinine>30%) in the month preceding randomization severe/uncontrollable adverse events with suspected relationship to everolimus (e.g. anemia, oral aphtosis, arthralgia) for the control of which (...) Everolimus Sirolimus Cyclosporins Cyclosporine Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic Antifungal Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Dermatologic Agents Antirheumatic Agents Calcineurin Inhibitors

2009 Clinical Trials

31780. Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma

Type : Interventional (Clinical Trial) Actual Enrollment : 257 participants Allocation: Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomized Phase I/II Study of ABT-888 in Combination With Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma Study Start Date : July 2010 Actual Primary Completion Date : May 2014 Actual Study Completion Date : December 2016 Resource links provided by the National Library (...) , or bone fracture Abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within the past 28 days Significant traumatic injury within the past 28 days Acute bacterial or fungal infection requiring IV antibiotics at the time of study registration Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within the past 14 days AIDS based upon current Centers for Disease Control and Prevention (CDC

2009 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>